KR20180033499A - 섬유증을 치료하는데 사용하기 위한 엔도스타틴 단편 및 변이체 - Google Patents

섬유증을 치료하는데 사용하기 위한 엔도스타틴 단편 및 변이체 Download PDF

Info

Publication number
KR20180033499A
KR20180033499A KR1020187000354A KR20187000354A KR20180033499A KR 20180033499 A KR20180033499 A KR 20180033499A KR 1020187000354 A KR1020187000354 A KR 1020187000354A KR 20187000354 A KR20187000354 A KR 20187000354A KR 20180033499 A KR20180033499 A KR 20180033499A
Authority
KR
South Korea
Prior art keywords
polypeptide
endostatin
seq
fibrosis
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187000354A
Other languages
English (en)
Korean (ko)
Inventor
캐롤 페갈리-보스트윅
테렌스 이 라이언
할 에스. 패드겟
매튜 맥기
Original Assignee
아이바이오, 인크.
노비치 바이오텍 엘엘씨
무스크 파운데이션 포 리서치 디벨롭먼트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이바이오, 인크., 노비치 바이오텍 엘엘씨, 무스크 파운데이션 포 리서치 디벨롭먼트 filed Critical 아이바이오, 인크.
Publication of KR20180033499A publication Critical patent/KR20180033499A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020187000354A 2015-06-05 2016-06-03 섬유증을 치료하는데 사용하기 위한 엔도스타틴 단편 및 변이체 Ceased KR20180033499A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562171889P 2015-06-05 2015-06-05
US62/171,889 2015-06-05
US201562257607P 2015-11-19 2015-11-19
US62/257,607 2015-11-19
PCT/US2016/035858 WO2016197018A1 (en) 2015-06-05 2016-06-03 Endostatin fragments and variants for use in treating fibrosis

Publications (1)

Publication Number Publication Date
KR20180033499A true KR20180033499A (ko) 2018-04-03

Family

ID=56236074

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187000354A Ceased KR20180033499A (ko) 2015-06-05 2016-06-03 섬유증을 치료하는데 사용하기 위한 엔도스타틴 단편 및 변이체

Country Status (10)

Country Link
US (2) US10844392B2 (cg-RX-API-DMAC7.html)
EP (1) EP3303383A1 (cg-RX-API-DMAC7.html)
JP (2) JP6952685B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180033499A (cg-RX-API-DMAC7.html)
CN (2) CN107849117B (cg-RX-API-DMAC7.html)
AU (2) AU2016270428B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017026209A2 (cg-RX-API-DMAC7.html)
CA (1) CA2988299C (cg-RX-API-DMAC7.html)
WO (1) WO2016197018A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708223B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197018A1 (en) * 2015-06-05 2016-12-08 Ibio, Inc. Endostatin fragments and variants for use in treating fibrosis
AU2019338416A1 (en) * 2018-09-14 2021-04-29 Akso Biopharmaceutical, Inc. sPD-1 variant - Fc fusion proteins
WO2021007094A1 (en) * 2019-07-10 2021-01-14 Musc Foundation For Research Development Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
US12454551B2 (en) * 2019-07-31 2025-10-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Peptides as inhibitors of fibrotic matrix accumulation
JP7493945B2 (ja) * 2020-01-28 2024-06-03 ポーラ化成工業株式会社 培養組織の観察方法、培養方法、評価方法及び培養器具
WO2022006601A1 (en) * 2020-07-02 2022-01-06 Northwestern University Human recombinant ace2-fc mutants that decouple anti-sars-cov-2 activity from cardiovascular effects
US20250195673A1 (en) * 2020-11-30 2025-06-19 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
EP4392056A4 (en) * 2021-09-07 2025-12-24 Musc Found For Res Dev Endostatin peptides for the treatment of tumors, fibrosis, and acute lung injury

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US750375A (en) 1904-01-26 Potato-digger
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ES2133271T3 (es) 1989-07-06 1999-09-16 Univ California Receptores para factores de crecimiento de fibroblastos.
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5756671A (en) 1994-06-02 1998-05-26 Mitotix, Inc. CDC37 cell-cycle regulatory protein, and uses related thereto
US6080560A (en) * 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6165460A (en) 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
DE19535939A1 (de) 1995-09-27 1997-04-03 Agfa Gevaert Ag Fotografisches Material
IL136667A0 (en) 1997-12-08 2001-06-14 Beth Israel Hospital Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999062944A2 (en) * 1998-06-03 1999-12-09 The Children's Medical Center Corporation Protein oligomer compositions comprising endostatin protein and methods of using the same
US6399075B1 (en) 1998-07-02 2002-06-04 President And Fellows Of Harvard College Compositions and methods for treating Papillomavirus-infected cells
WO2000046350A1 (en) 1999-02-05 2000-08-10 Thomas Jefferson University Production of biomedical peptides and proteins in plants using transcomplementation systems
US6656728B1 (en) 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
ES2531125T3 (es) 2003-02-03 2015-03-10 Ibio Inc Sistema para la expresión de genes en plantas
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
JP2010531666A (ja) * 2007-06-26 2010-09-30 ユニバーシティ オブ マイアミ 抗体−エンドスタチン融合タンパク質及びそのバリアント
WO2011050311A1 (en) 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
BR112014001268A2 (pt) * 2011-07-19 2017-02-21 Thrasos Innovation Inc peptídeos antifibróticos e seu uso em métodos para tratamento de doenças e distúrbios caracterizados por fibrose
WO2016197018A1 (en) 2015-06-05 2016-12-08 Ibio, Inc. Endostatin fragments and variants for use in treating fibrosis

Also Published As

Publication number Publication date
AU2021200765A1 (en) 2021-03-04
AU2016270428A1 (en) 2018-01-25
WO2016197018A1 (en) 2016-12-08
EP3303383A1 (en) 2018-04-11
CN107849117B (zh) 2022-08-26
CN107849117A (zh) 2018-03-27
JP2022002527A (ja) 2022-01-11
US20180179263A1 (en) 2018-06-28
CN115925878A (zh) 2023-04-07
JP6952685B2 (ja) 2021-10-20
AU2016270428B2 (en) 2020-11-26
US20210108221A1 (en) 2021-04-15
CA2988299A1 (en) 2016-12-08
US11912755B2 (en) 2024-02-27
JP7404320B2 (ja) 2023-12-25
WO2016197018A9 (en) 2017-01-19
BR112017026209A2 (pt) 2018-11-27
WO2016197018A8 (en) 2017-07-13
JP2018524019A (ja) 2018-08-30
AU2021200765B2 (en) 2023-04-13
US10844392B2 (en) 2020-11-24
CA2988299C (en) 2023-10-31
ZA201708223B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
AU2021200765B2 (en) Endostatin fragments and variants for use in treating fibrosis
JP7517997B2 (ja) プログラニュリンを含む融合タンパク質
JP6249949B2 (ja) 薬物動態特性の改善されたコンプスタチンアナログ
US10709769B2 (en) Use of endostatin peptides for the treatment of fibrosis
KR20170033372A (ko) 인터루킨-23 수용체의 경구용 펩티드 억제제 및 염증성 장 질환을 치료하기 위한 그의 용도
JP2012521360A (ja) Ｋｖ１．３の選択的かつ強力なペプチド阻害剤
TW200944226A (en) Biologically active peptides
CN114573686A (zh) 含有二硫键且具有抑制丝氨酸蛋白酶活性的多肽及其应用
US20180244792A1 (en) Anti-fibrotic effect of cd70
WO2013156771A1 (en) Anti-atherogenic peptides
CN100480264C (zh) 一种广谱抑制癌细胞生长的蚯蚓蛋白及其编码序列
EA049541B1 (ru) Слитые белки, содержащие програнулин
EA049817B1 (ru) Варианты програнулина
HK40046687A (en) Fusion proteins comprising progranulin

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180105

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210525

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230410

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231212

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230410

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I